Key result
TAVI shows feasibility in bicuspid aortic valve disease with newer devices but demands careful MSCT planning.
This review summarizes the current evidence, anatomical challenges, and practical considerations for performing TAVI in patients with bicuspid aortic valve disease.
Answers are grounded in this paper and cite their sources.
Supports selective TAVI in bicuspid disease with MSCT planning; leaves open randomized confirmation of safety in lower-risk patients.
Patients with bicuspid aortic valve disease have systematically been excluded from large randomised clinical trials investigating transcatheter aortic valve implantation (TAVI) due to their younger age, lower surgical risk and complex aortic anatomy. The asymmetric nature of the bicuspid valve orifice often accompanied by heavy regional calcification has led to concerns regarding valve positioning and expansion. Bicuspid aortic valve disease patients are at heightened risk of TAVI-related complications including coronary occlusion, aortic dissection and annular rupture, as well as the known risks of progressive aortopathy in these patients. These unique anatomical characteristics pose challenges for TAVI operators. However, with recent and ongoing refinements in implantation technique, improvements in pre-procedural imaging and iterations in device design, TAVI is emerging as a safe and feasible treatment option in this population. Paravalvular aortic regurgitation and high pacemaker rates have been the Achilles Heel for TAVI in bicuspid valve patients, yet newer generation devices are yielding promising results. Further studies are required before TAVI ultimately emerges as a viable option in low and intermediate surgical-risk patients with bicuspid valve disease. This review comprehensively summarizes the epidemiology, pathology and current evidence for TAVI in patients with bicuspid aortic valve disease. We also outline some practical tips for performing TAVI in these patients.
No takes yet. Share an insight, caveat, or question.
Das et al. (2018) conducted a review in Bicuspid aortic valve disease with severe aortic stenosis. Transcatheter Aortic Valve Implantation (TAVI) was evaluated. TAVI is emerging as a feasible treatment option for bicuspid aortic valve disease using newer generation devices, though it requires careful pre-procedural MSCT planning due to unique anatomical challenges.
Synapse has enriched 10 related papers. Consider them for comparative context: